RxDoctor Payments Data

Danielle Stramandi, MD

Family Medicine · San Antonio, TXNPI 1831419399

Payments from drug & device makers

$7,552in general payments, 2019–2025

Across 197 payments — averaging $38.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$875
  • Lilly USA, LLC$734
  • AstraZeneca$570
  • Boehringer Ingelheim$421
  • Corcept Therapeutics$397
  • Amgen$385
  • plus $4K from 38 others

What the payments were for

  • Food & beverage$7,545100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,552 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$24,984
Medicare patients
75
Services billed
325

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin13$10,588
MyrbetriqMirabegron12$5,069
FenofibrateFenofibrate Nanocrystallized16$1,300
SynthroidLevothyroxine Sodium15$1,278
Estradiol (Twice Weekly)Estradiol15$903
Duloxetine Hcl12$826
Levothyroxine Sodium49$466
Bupropion XlBupropion Hcl11$400
Atorvastatin Calcium35$290
Losartan Potassium23$236
Metoprolol Succinate22$231
Rosuvastatin Calcium22$211
Metformin Hcl ErMetformin Hcl12$198
Pantoprazole Sodium21$189
Trazodone Hcl19$189

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$421$10,58813 claims
Astellas Pharma US IncMyrbetriq$62$5,06912 claims
AbbVieSynthroid$339$1,27815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →